IL-1 family members in cancer; two sides to every story by Baker, Kevin J. et al.
UCC Library and UCC researchers have made this item openly available.
Please let us know how this has helped you. Thanks!
Title IL-1 family members in cancer; two sides to every story
Author(s) Baker, Kevin J.; Houston, Aileen M.; Brint, Elizabeth K.
Publication date 2019-06-07
Original citation Baker, K. J., Houston, A. and Brint, E. (2019) 'IL-1 Family Members in
Cancer; Two Sides to Every Story', Frontiers in Immunology, 10, 1197
(16 pp). doi: 10.3389/fimmu.2019.01197




Access to the full text of the published version may require a
subscription.
Rights © 2019 Baker, Houston and Brint. This is an open-access article
distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other
forums is permitted, provided the original author(s) and the
copyright owner(s) are credited and that the original publication in
this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not







published: 07 June 2019
doi: 10.3389/fimmu.2019.01197
Frontiers in Immunology | www.frontiersin.org 1 June 2019 | Volume 10 | Article 1197
Edited by:
Diana Boraschi,




Ben-Gurion University of the Negev,
Israel
Francesca Oliviero,




†These authors have contributed
equally to this work
Specialty section:
This article was submitted to
Cytokines and Soluble Mediators in
Immunity,
a section of the journal
Frontiers in Immunology
Received: 18 March 2019
Accepted: 13 May 2019
Published: 07 June 2019
Citation:
Baker KJ, Houston A and Brint E
(2019) IL-1 Family Members in
Cancer; Two Sides to Every Story.
Front. Immunol. 10:1197.
doi: 10.3389/fimmu.2019.01197
IL-1 Family Members in Cancer; Two
Sides to Every Story
Kevin J. Baker 1,2,3, Aileen Houston 2,4† and Elizabeth Brint 1,4*†
1Department of Pathology, University College Cork, Cork, Ireland, 2Department of Medicine, University College Cork, Cork,
Ireland, 3 APC Microbiome Ireland, University College Cork, Cork, Ireland, 4CancerResearch@UCC, University College Cork,
Cork, Ireland
The IL-1 family of cytokines currently comprises of seven ligands with pro-inflammatory
activity (IL-1α and IL-1β, IL-18, IL-33, IL-36α, IL-36β, IL-36γ) as well as two ligands with
anti-inflammatory activity (IL-37, IL-38). These cytokines are known to play a key role in
modulating both the innate and adaptive immunes response, with dysregulation linked to
a variety of autoimmune and inflammatory diseases. Given the increasing appreciation of
the link between inflammation and cancer, the role of several members of this family
in the pathogenesis of cancer has been extensively investigated. In this review, we
highlight both the pro- and anti-tumorigenic effects identified for almost all members of
this family, and explore potential underlying mechanisms accounting for these divergent
effects. Such dual functions need to be carefully assessed when developing therapeutic
intervention strategies targeting these cytokines in cancer.
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INTERLEUKIN-1 SUPERFAMILY
Introduction
The importance of inflammation in cancer is now well established (1–3). In some cancers, the
inflammatory conditions precede the development of malignancy, e.g., chronic bronchitis is a
major risk factor for lung cancer. Alternatively, aberrant signaling due to oncogenic mutations
in tumors can result in a chronic inflammatory state developing both proximal to, and within, the
tumor. This chronic inflammation acts to inhibit the anti-tumorigenic immune response, normally
mediated by cells such as M1 macrophages, NK cells and CD8+ T cells. Tumor cells themselves
can also directly induce an immunosuppressive microenvironment through recruitment and
activation of specific immune cell subtypes such as myeloid derived suppressor cells (MDSC), M2
macrophages and T regulatory cells, further promoting tumorigenesis (2, 4, 5). Understanding
the complexity of immunomodulation by tumors is important for the development of effective
immunotherapies. Cytokines, such as Interleukin-1 (IL-1) are central mediators of the interactions
between cells in the inflammatory tumor microenvironment. The IL-1 family now includes seven
ligands with pro-inflammatory activity (IL-1α and IL-1β, IL-18, IL-33, IL-36α, IL-36β, IL-36γ)
as well as anti-inflammatory cytokines (IL-37, IL-38). Several members of this family, such as
IL-1β and IL-18, have been extensively investigated in cancer with both pro- and anti-tumorigenic
functions ascribed to these cytokines. In contrast, far less is currently understood concerning the
role of more recently identified members of this family in cancer such as IL-33 and IL-37, although
such data that is available also indicates that these may have both pro- and anti- tumorigenic effects.
In this review, we will explore the dual functions of these cytokines in the tumorigenic process.
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INTERLEUKIN-1 (IL-1)
As IL-1 was the original defining member of its family, its
physiological function and indeed, pathophysiological function,
has been extensively studied and reviewed (6). The triumvirate
of cytokines grouped under the heading of IL-1 includes two of
the activator cytokines IL-1α and IL-1β, as well as an inhibitory
cytokine, the IL-1 receptor antagonist. IL-1α and IL-1β bind the
same receptor, the type 1 IL-1 receptor (IL-1R), recruiting both
the IL-1R accessory protein and the adaptor protein MyD88 to
the receptor complex, resulting in activation of the downstream
signaling cascade and ultimately in the activation of a myriad
of immune and inflammatory genes (7). Whilst these cytokines
activate through the same pathway, they are separately encoded
proteins with a low level of sequence homology and well
characterized divergent biological processes, cellular localization
and mechanisms of activation. Both IL-1α and IL-1β exist as
pro-forms and cleaved forms, but whereas both forms of IL-
1α are biologically active, only the cleaved form of IL-1β acts
as a pyrogen. IL-1α is grouped in a category of dual function
cytokines (with IL-33 and IL-37), as it is located both within the
nucleus of the cell where it plays a role in transcription (8), and
also as a functional membrane bound cytokine. In addition, IL-
1α is released from necrotic cells allowing it to function as an
“alarmin.” In contrast, the processing and bioavailability of IL-
1β is very tightly controlled. We now know that IL-1β requires
a “two-signal” process to become activated (9), with the initial
priming signal triggering transcription of the gene and the second
signal, resulting in inflammasome activation, allowing caspase-
1 mediated cleavage and activation of IL-1β. It is therefore, not
surprising that these two cytokines, so often grouped together,
have been shown to have different physiological and biological
effects in many human diseases and indeed, with relevance to this
review, in different cancer types (10). Also, as with somany of this
family of cytokines, divergent pro- and anti- tumorigenic effects
have been reported for both. Here we will detail some of these
alternate functions ascribed to both cytokines.
IL-1α
Tumor-Promoting Effects of IL-1α
Whilst there is no shortage of data supporting a role for IL-
1β in tumorigenesis, there are relatively fewer studies directly
examining IL-1α in cancer development and progression. IL-
1α expression has been reported to be significantly increased
in head and neck squamous carcinoma (HNSCC) patients with
distant metastasis as compared to those without metastasis
(11). A similar correlation between IL-1α expression and
distant liver metastasis has been reported in patients with
gastric carcinoma (12). High levels of IL-1α expression in
cancers have also been linked to tumor dedifferentiation
(13) and lymphangiogenesis (14). Associations between single
nucleotide polymorphisms in the IL-1α gene and cancer
risk have been identified (15) with carriers of the rs17561
missense mutation showing reduced susceptibility to clear cell
ovarian cancer.
Both in vitro and in vivo evidence have supported this clinical
data. Interestingly, both forms of IL-1α have been shown to
have potential tumor promoting effects (16) as the pro-piece,
nuclear form of IL-1 has been shown to facilitate the growth
of acute T-lymphocytic leukemia cells through the activation
of NF-κB and SP1. Stable overexpression of IL-1α in the
normally non-metastatic IL-1α negative pancreatic carcinoma
cell line MIaPaCa-2 enhanced NF-κB production and cellular
invasion in vitro (17), and resulted in liver metastasis following
orthotopic injection in murine models. Moreover, co-culture of
pancreatic ductal adenocarcinoma cells with cancer-associated
fibroblasts (CAFs) resulted in marked upregulation of multiple
inflammatory factors including IL-1α. Inhibition of IL-1α alone
reduced the crosstalk-induced production of these inflammatory
factors (18), indicating a key role for IL-1α in the formation
and maintenance of the inflammatory tumor environment.
Pancreatic cancer cell-derived IL-1α was similarly shown to
promote hepatocyte growth factor secretion by fibroblasts
(19), promoting pancreatic cancer invasion, proliferation and
angiogenesis. IL-1α expression was also essential for tumor
development following implantation of the 3-MCA-induced
fibrosarcoma cell line (20), with findings from this study
highlighting an important role for IL-1α in controlling immune-
surveillance of the developing tumor. A similar role for Il-
1α was recently demonstrated in breast cancer (21). Breast
tumor-derived IL-1α, acting on tumor-infiltrating myeloid cells,
induced the expression of thymic stromal lymphopoietin (TSLP),
which was not only a critical tumor survival factor, but is
also required for the metastatic spread of the tumor cells.
These studies define a novel IL-1α-TSLP-mediated crosstalk
between tumor-infiltrating myeloid cells and tumor cells in the
control of metastatic breast cancer. Finally, recent elegant work
examining the relationship between HER2 expression in breast
cancer, inflammation and expansion of cancer stem cells (CSCs)
highlighted an essential role for IL-1α in this process (22). These
authors demonstrate that HER2 expression in the tumor drives
a positive feed-forward activation loop, inducing the expression
of IL-1α and IL-6. This, in turn, increases activation of NF-
κB and STAT3, allowing for the generation and maintenance of
CSCs. IL-1α- deficient mice show delayed MMTV-Her2-induced
tumorigenesis, reduced inflammation and reduced numbers of
CSCs. Moreover, pharmacologic blockade of IL-1α signaling
reduced the population of CSCs in the tumors, and improved
chemotherapeutic efficacy (22).
Given these tumor-promoting functions for IL-1α, studies
have investigated whether it represents a potential therapeutic
target for cancer therapy. MABp1 (XBiotech Inc.) is a naturally
occurring human IL-1α neutralizing antibody which has shown
promising outcomes in several cancer types (23, 24). Also, a
recent randomized phase III trial by Kurzrock et al. showed
patients with advanced colorectal cancer and lower levels
of circulating IL-1Ra are more responsive to treatment with
bermekimab, an antibody targeting IL-1α. Levels of IL-1Ra were
shown to be reflective of the potentiated response from antibody
administration (25). Further work in this field will identify
whethermechanisms for neutralizing IL-1α can be optimized and
made viable for cancer therapy.
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Tumor-Suppressive Effects of IL-1α
In contrast to the above findings, studies have shown that,
particularly transient, overexpression of IL-1α may have anti-
tumorigenic effects. Both fibrosarcoma and lymphoma cells were
induced to express IL-1α in a transient manner. Of note, in this
model IL-1α was expressed in the cytosol and not excreted. The
IL-1α-expressing tumor cells were seen to predominantly not
result in tumor development. Furthermore, if tumors did occur,
they subsequently regressed. Tumor regression was observed to
be mainly mediated by CD8+ T cells, with some involvement
of NK cells and macrophages (26, 27). Moreover, stimulation of
multiple cancer cell lines, including MCF-7 breast cancer, A375
melanoma, prostate stem cells and murine primary mammary
cells, with IL-1α inhibited cell proliferation by causing G0–G1
cell cycle arrest. (28–30). More recently, a study investigating
the role of the IL-1R in tumorigenesis indicated that IL-1R
signaling could suppress mammary tumor cell proliferation
in the MMTV-PyMT breast cancer mouse model (31). This
phenotype was shown to be IL-1α dependant, indicating that
IL-1α-IL1R signaling may be tumor-suppressive in PyMT-driven
breast cancer.
IL-1β
Tumor-Promoting Effects of IL-1β
Evidence supporting a pro-tumorigenic role for IL-1β across
all cancer types has been accumulating over many years and
has been extensively reviewed in recent times (30). Solid
tumors in which IL-1β has been shown to be upregulated
include breast, colon, lung, head and neck cancers, and
melanomas, and patients with IL-1β producing tumors generally
exhibit a poorer prognosis (32). Multiple strands of both in
vitro and in vivo evidence point toward a tumor-promoting
function for IL-1β. Fibrosarcoma cells, genetically modified to
constitutively excrete mature IL-1β, show increased growth,
invasiveness and angiogenesis (33). Indeed, clear associations
have been demonstrated between IL-1β and angiogenesis in
multiple tumor types (34, 35). In a transgenic model of Myc-
dependent carcinogenesis, IL-1β has been characterized as the
principal effector molecule in the onset of angiogenesis (36).
Mechanistically, this was seen to be mediated via matrix
metalloproteinase (MMP) -induced sequestration of extracellular
matrix–associated vascular endothelial growth factor (VEGF),
followed by its ligation to VEGFR2 on endothelial cells.
Moreover, in a model of melanoma, myeloid cells was shown
to produce IL-1β (37), which subsequently activated endothelial
cells to produce VEGF and other proangiogenic factors,
modulating the inflammatory microenvironment of the tumor,
allowing for enhanced angiogenesis and tumor progression.
As could be predicted based on its ability to enhance
angiogenesis, IL-1β has also been shown, in multiple models
across multiple cancer types, to enhance tumor cell metastasis.
In both murine and human breast cancer models, tumor
progression was associated with the activation of inflammasome
components and subsequent elevated levels of IL-1β at
primary and metastatic sites. Mice deficient for inflammasome
components exhibited significantly reduced tumor growth and
lung metastasis (38). Similar findings have been shown for
the NLRP3 inflammasome in lymphangiogenesis and metastasis
(39). Macrophage-dependent lymphangiogenesis was triggered
upon inflammasome activation and required IL-1β production.
NLRP3 expression in tumor-infiltrating macrophages also
correlated with survival, lymph node invasion, and metastasis of
mammary carcinoma patients (39). The role of IL-1β in driving
expression and production of downstream pro-tumorigenic
cytokines appears to play a key role in this process. IL-1β induces
IL-6 production in breast cancer cells, as well as additional
cytokines and growth factors including TGF-β, TNF-α, and EGF.
Indeed, these cytokines and growth factors seem to potentiate
the effect of IL-1β on IL-6 expression. In breast cancer cells,
epithelial-to-mesenchymal (EMT) and stem-cell-like phenotypes
were attenuated by either anti-IL-6 or anti-IL-1β antibody
treatment (40). A similar causal link between IL-1β and IL-22
has recently been established (41). IL-22 is now emerging as a
cytokine with potent tumor-promoting properties. It has recently
been shown that IL-22 production in humans is dependent on
activation of the NLRP3 inflammasome with the subsequent
release of IL-1β from both myeloid and T cells. The IL-1 receptor
antagonist Anakinra abrogates IL-22 production and reduces
tumor growth in a murine breast cancer model (40).
Based on these, and many other (42), findings, IL-1β is now
viewed as an attractive target for pharmacological intervention.
Several agents are available including IL-1Ra (Anakinra) which
inhibits both IL-1α and IL-1β signaling, neutralizing antibodies
to IL-1β (Canakinumab), as well as inflammasome inhibitors.
It has recently been shown that administration of inhibitory
antibodies targeting IL-1β results in the augmentation of anti-
tumor cell immunity in a murine model of breast cancer. A
synergistic effect of anti-IL-1β and anti-PD-1 treatment with
antibodies was capable of altering TME cell populations in favor
of an anti-tumor phenotype (43). In clinical trials, Anakinra has
been shown to inhibit IL-6 production and enhance the progress-
free survival of patients with indolent myeloma (44). Moreover,
a recent comprehensive study convincingly demonstrated that
Anakinra may also be beneficial in the treatment of breast
cancer (43). In this study, production of IL-1β in primary
breast cancer tumors was linked with advanced disease. IL-
1β was shown to originate from tumor-infiltrating CD11c+
myeloid cells with production triggered by cancer cell-derived
TGFβ. Administration of anakinra prevented breast cancer
progression in humanized mouse model. Moreover, a pilot
clinical trial wherein 11 patients with Her2− metastatic breast
cancer were treated with daily subcutaneous Anakinra for a
median duration of 4 months, in combination with one of
the standard chemotherapeutics, demonstrated that high risk
Her2− breast cancer patients would benefit from reducing levels
of IL-1β and treatment with anakinra (45, 46). Excitingly, a
recent phase three clinical trial (CANTOS) (45) demonstrated
that an inhibitory antibody targeting IL-1β (canakinumab) could
significantly reduce the incidence and mortality of lung cancer.
Although this trial involving 10,500 patients was not initially
designed to study lung cancer as an end-point, analysis revealed
that there was a 56% reduction in incident lung cancer in the
canukinumab-treated group as compared to the placebo group.
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As these patients were extensively screened prior to recruitment,
the indication is that inhibition of IL-1β reduced the progression,
invasiveness andmetastatic spread of early stage lung cancers that
were undiagnosed at time of recruitment. These data emphasize
the importance of this cytokine in chronic inflammation in lung
tumorigenesis, and its validity as a therapeutic target.
Tumor Inhibiting Effects of IL-1β
The divergent and conflicting role of the IL-1 cytokines is
particularly apparent when investigating IL-1β. The majority of
these studies highlight the ability of IL-1β to induce both Th1
and Th17 responses and thus to induce anti-tumorigenic effects.
Exogenous injection of IL-1β resulted in tumor regression, as
long as the tumors were of a sufficient size, and the mice
were not deficient in T cells (47). Haabeth and colleagues also
demonstrated that IL-1β drives activation of tumor specific
Th1 responses, thus protecting against B cell myeloma and
lymphoma (48, 49). Contrasting tumor-inhibiting effects have
also been ascribed to IL-1β in the case of colorectal cancer (CRC).
Inhibition of the NLRP3 inflammasome was seen to reduce
tumor burden in the murine model of colitis-associated cancer,
with the increased tumor burden correlating with attenuated
levels of IL-1β and IL-18 at the tumor site (50). An insight into
the underlying mechanism concerning the dichotomous role of
IL-1β in CRC was recently provided. Dmitrieva-Posocco and
colleagues examined the impact of IL-1 signaling in different
cell types within the CRC microenvironment (51). Analysis of
epithelial cell specific IL-1R1 deletion revealed a decrease in CRC
tumor multiplicity, slower proliferation of early tumor seeds, and
decreased activation of NF-κB. T cell specific ablation of IL-1R1
similarly decreased tumor-elicited inflammation dependent on
IL-17 and IL-22, thereby reducing CRC progression. In contrast,
IL-1 signaling in myeloid, particularly neutrophil populations,
was shown to be potently anti-tumorigenic due to their role
in controlling the local microbiota populations. These authors
demonstrate that IL-1R signaling in myeloid cells is responsible
for keeping specific species/genera of tumor infiltrating microbes
at bay, thus preventing local, tumor-specific dysbiosis and
excessive amounts of pro-tumorigenic inflammatory cytokines.
Interesting interactions between primary tumors and distant
metastatic sites in breast cancer, involving IL-1β, have also
recently been elegantly described. These authors demonstrate
that certain primary tumors elicit a systemic inflammatory
response involving IL-1β-expressing innate immune cells that
then infiltrate distant metastatic microenvironments. At the
metastatic site, IL-1β maintains metastatic cells in a ZEB1-
positive differentiation state, preventing them from establishing
themselves. In line with these findings (52), the authors further
demonstrate that inhibition of the IL-1 receptor relieves the
differentiation block and results in metastatic colonization, and
that among patients with lymph node-positive breast cancer, high
primary tumor IL-1β expression is associated with better overall
survival and distant metastasis-free survival. Contrasting this,
however, Li et al have provided evidence indicating an opposing
role of IL-1β through ZEB1 activation resulting in the promotion
of stemness and invasion of colon cancers cells (53). It is clear,
therefore, that these dichotomous findings regarding IL-1β need
to be carefully considered when developing anti-cancer therapies
designed to inhibit IL-1β. The divergent roles of IL-1β in cancer
are shown in Figure 1.
INTERLEUKIN-18
Interleukin-18 (IL-18) (also known as IFN-γ-inducing factor)
was first identified in 1989 (54) as a factor that enhanced IFN-
γ production from anti-CD3-stimulated Th1 cells, especially in
the presence of IL-12. Subsequent isolation and characterization
of the cytokine determined that its structure was similar to
that of IL-1 (55). Similar to IL-1β, IL-18 is synthesized as
an inactive 24kDa pro-peptide that is activated by proteolytic
cleavage by caspase-1 in the NLRP3 inflammasome, generating
the mature, bioactive, 18 kDa molecule. The IL-18 receptor
(IL-18R) consists of the inducible component IL-18Rα (IL-
1 receptor-related protein [IL-1Rrp]) and the constitutively
expressed component IL-18Rβ (IL-1R accessory protein-like [IL-
1RAcPL]), and activates a similar pathway to that of IL-1 (55).
The activity of IL-18 is suppressed following binding by the high
affinity, naturally occurring IL-18 binding protein (IL-18BP),
which prevents IL-18 binding to its receptor. IL-18 is expressed
by many cell types and plays an important role in both the innate
and adaptive immune response (56).
Tumor-Promoting Effects of IL-18
Numerous studies have investigated the role of IL-18 in cancer,
with both pro- and anti-tumorigenic functions identified (56).
Some of the first evidence that IL-18 can promote tumor growth
came from the observation of elevated expression of IL-18
by tumor cells or elevated levels of IL-18 in the serum of
cancer patients, with elevated levels of IL-18 associated with
poor prognosis (57–59). These high levels of IL-18 may play
a role in angiogenesis, tumor cell migration, invasion and
metastasis. Indeed, studies in gastric cancer showed that IL-18
induces the expression of the pro-angiogenic factor, vascular
endothelial growth factor (VEGF) (60). VEGF, in turn, can
increase the expression and processing of IL-18 (61, 62), with IL-
18 increasing cell migration directly through filamentous-actin
polymerization and tensin downregulation (61, 62). Consistent
with cell migration and angiogenesis being key steps in tumor
metastasis, suppression of IL-18 expression in gastric cancer
cells resulted in a reduction in both primary tumor growth and
metastasis in vivo. Moreover, angiogenesis was greatly reduced in
tumors lacking IL-18 relative to control tumors (60).
Additional mechanisms proposed for the migratory and
metastatic ability of IL-18 involve alterations in expression of
adhesion molecules and tight junction proteins (63–65). For
instance, administration of IL-18BP significantly suppressed
melanoma cell metastasis to the liver by preventing IL-18-
induced expression of adhesion molecules such as vascular
cell adhesion molecule-1 (VCAM-1) on hepatic sinusoidal
endothelial cells (63). Exogenous IL-18 also enhanced the
migration of breast cancer cells (65), and this was due to
suppression of expression of the tight junction proteins, in
particular, claudin-12.
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FIGURE 1 | Functions of IL-1β signaling in cancer. The IL-1 signaling pathway is activated through the binding of IL-1α or IL-1β to the IL-1RI. This is followed by
dimerization of IL-1R1 with IL-1RAcP. This interaction may be competitively inhibited by the IL-1RA and IL-38. Agonist binding is followed by engagement of further
signaling intermediates with subsequent activation of transcription factors such as NF-κB and AP-1. Transcription of inflammatory genes is upregulated which may
then result in pro-tumorigenic or anti-tumorigenic phenotypes.
Other tumor-promoting effects associated with IL-18 include
evasion of the anti-tumor immune response. Natural Killer (NK)
cells, if appropriately activated, play an important role in tumor
rejection. However, NK cells can also have immunosuppressive
effects. Administration of recombinant IL-18 was shown to
up regulate the expression of PD-1 by conventional NK cells,
and to convert them into a subset with immunosuppressive
characteristics (66, 67). Silencing of IL-18 or blockade of IL-
18 activity with IL-18BP, in turn, led to the restoration of
NK cell-dependent immune surveillance in tumors (67). IL-18
has also been implicated in the generation of myeloid derived
suppressor cells (MDSC). MDSC are potent suppressors of
the anti-tumor immune response, with administration of IL-18
shown to increase the population of MDSC in multiple myeloma
and in a murine model of melanoma (68, 69). Together, these
studies suggest that targeting IL-18 may represent a potential
mechanism to overcome tumor-associated immunosuppression.
However, phase 2 clinical trials for metastatic melanoma
by GSK utilizing a recombinant human IL-18 (Iboctadekin)
demonstrated insufficient clinical benefit (70). It is possible,
however, that combining an IL-18 targeting strategy with
additional chemotherapeutic reagents could be a better
approach in the treatment of patients with cancer. Indeed,
a dose-escalation study of recombinant Iboctadekin in
combination with rituximab (anti-CD20) was well tolerated
and showed increased production of IFN-γ, GM-CSF and
chemokines in a pilot study of 5 patients with non-Hodgkin’s
lymphoma (71).
Tumor-Inhibiting Effects of IL-18
IL-18, however, has also be shown to activate the anti-
tumor immune response, resulting in the suppression of tumor
growth and metastasis in multiple tumor types. For instance,
administration of recombinant IL-18 has been shown to activate
CD4+ T cells and/or NK cell immune responses, suppressing
the growth and metastasis of melanoma cells in vivo (72).
Consistent with this, individuals with low NK cell activity have
an increased risk of developing cancer (73), with high numbers of
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intratumoral NK cells often correlated with improved prognosis
for cancer patients (74, 75).
These opposing effects described for IL-18 in tumorigenesis
could be due to the level of IL-18 administered and/or present
in the tumor microenvironment (67). For instance, low doses
of IL-18 were shown to accelerate tumor progression (66), in
part through the induction of Kit+ immunosuppressive NK
cells, while daily administration of IL-18 induced inflammation
and increased the anti-tumor response, thus suppressing tumor
growth. The function of IL-18 in cancer could also depend
on cytokines present at the site of NK cell activation and
maturation. Recent studies have shown that incubation of NK
cells with IL-18, IL-12, and IL-15 results in the generation
of cytokine-induced memory-like (CIML) NK cells, which
have enhanced cytokine (IFN-γ) production and exhibit potent
anti-tumor effects against both hematological (76) and non-
hematological malignancies (77). Studies aimed at establishing
protocols for the in vitro generation of tumor-suppressive
NK cells determined that radiation therapy greatly increased
the number and function of the transferred NK cells, and
was essential for the anti-tumor activity of transferred CIML
NK cells (78). Thus, harnessing cytokine-induced memory-like
NK cell responses could represent a promising translational
immunotherapy approach for patients with malignant disease.
Given the studies demonstrating an anti-tumorigenic function
for IL-18, numerous strategies are being investigated aimed at
increasing the level of IL-18 in the tumor microenvironment
and thus to augment the anti-tumor immune response. This
includes the engineering of oncolytic adenoviruses co-expressing
IL-18 and IL-12 (79). Intratumoral administration of these
adenoviruses improved the anti-tumor immune response in the
B16-F10 murine melanomamodel, in part though the generation
of an effective T-cell mediated immune response. Bacteria have
also been used to deliver IL-18 into the tumor microenvironment
to augment the T-cell mediated immune response (80). IL-
18-producing attenuated Salmonella typhimurium inhibited the
growth of primary subcutaneous tumors as well as pulmonary
metastases in immunocompetent mice challenged with syngeneic
multidrug-resistant clones of murine carcinoma cell lines,
without overt toxicity to normal tissues.
INTERLEUKIN-33
Initially identified as a nuclear factor, IL-33 was later determined
to be a ligand for the receptor ST2 (Fit-1/IL-33R/ IL1RL1).
A decoy receptor, sST2, has been found to be integral to the
regulation and attenuation of the IL-33/ST2 axis, similar to
that of IL1-R2 in interleukin-1 signaling (81, 82). IL-33 is
expressed by a diverse range of cells, with the strongest expression
observed in non-haematopoietic cells including endothelial cells,
epithelial cells, keratinocytes, fibroblasts, fibrocytes and smooth
muscle cells. Its receptor, ST2, is strongly expressed on the
surface of fibroblasts and hematopoietic cells such as T helper
type 2 (Th2) lymphocytes, ILC2s and mast cells. The IL-
33/ST2 pathway has been investigated in many inflammatory
diseases and dysregulation of this pathway has been particularly
implicated in Th2-mediated conditions such as allergic diseases
(83). The IL-33/ST2 signaling axis has been linked to processes
involved in wound healing such as angiogenesis, production of
matrix components, to fibrosis, and to modulation of immune
populations (84). Given the critical importance of such pathways
in tumor formation, links between the IL-33/ST2 signaling axis
and tumorigenesis have recently been identified, with multiple
research groups implicating IL-33 as a key player in themediation
of neoplastic transformation, tumor growth and metastasis in
various cancers including breast, gastric, colorectal and lung
(85). In parallel with other IL-1 family members, both pro- and
anti-tumorigenic roles have been reported for IL-33 in cancer.
Tumor Promoting Effects of IL-33
Several studies have examined expression of IL-33 and ST2, and
their association with patient prognosis. IL-33 and ST2 are both
elevated in comparison to adjacent healthy tissue in breast cancer,
with serum levels of IL-33 and its decoy receptor soluble ST2
(sST2) also elevated. These expression changes also correlated
with markers of poor prognosis (86). Similarly, expression of IL-
33 was found to be increased when compared to adjacent healthy
tissue in patients with both non-small-cell lung carcinoma
(NSCLC) (87) and epithelial ovarian cancer (88). Maywald et al
showed expression of IL-33 to be induced in colorectal cancer
at both mRNA and protein levels in patient-derived cell lines,
adenocarcinoma biopsies and in the systemic circulation of CRC
patients as compared to adjacent non-tumor tissue (89).
Much of the early work examining IL-33 in tumorigenesis
focussed on the role of IL-33 in breast cancer. Deletion of ST2
in BALB/c mice bearing mammary carcinoma attenuated tumor
growth and metastasis (90). This was accompanied by increased
serum levels of IL-17, IFN-γ and TNF-α, and decreased IL-4.
Suppressing sST2 reduced ErbB2-induced cell motility in breast
cancer cells (91). In a subsequent study (92), administration
of exogenous IL-33 to breast cancer-bearing mice was seen to
enhance tumor growth andmetastasis. The mechanism proposed
to be responsible for the enhanced tumor growth involves the
ability of IL-33 to cause an increase in the number of infiltrating
immunosuppressive immune cells and innate lymphoid cells
to the tumors, drive the tumorigenic process. Subsequent in
vitro and in vivo work on multiple cancer types have confirmed
these findings, with a similar IL-33-induced immuno-suppressive
microenvironment reported to play a tumor-promoting role in,
amongst others, CRC, gastric cancer, lung cancer, head and neck
cancers, pancreatic cancers and cervical cancer (93).
A role for IL-33 in the classic tumorigenic processes such
as EMT, proliferation, migration and invasion, has now been
extensively studied (84). Stromal CAFs are the main type of
non-immune cells in the tumor microenvironment (TME), with
CAFs known to interact with cancer cells to promote tumor
proliferation. IL-33-producing CAFS have been implicated as
a critical mediator in CAF-induced invasiveness in head and
neck squamous cell carcinoma (HNSCC) (94). In this cancer
type, administration of IL-33 promotes cancer cell migration
and invasion through induction of EMT. In oral squamous cell
carcinoma (OSCC), an interplay between a long non-coding
(lnc)-RNA strongly upregulated in CAFs and IL-33 was recently
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established. IL-33 was found to be co-expressed with this lnc-
CAF, resulting in elevation in the expression of CAF markers,
conversion of the normal fibroblast phenotype to stromal
carcinoma-related fibroblasts and enhanced tumor growth. This
was achieved by the lnc-CAF promoting IL-33 stability (95).
Intestinal epithelial cells, in turn, have been shown to use
epidermal growth factor (EGF) as a key factor to modulate IL-
33 production in cells. Inhibition of the EGF receptor resulted in
lower levels of IL-33 transcripts, with increased EGF stimulation
resulting in increased expression of ST2 and IL-33 (96). IL-33 has
also been shown to promote tumor cell growth, colony formation
and expression of Ki-67 and proliferating cell nuclear antigen
(PCNA) in a PGE2 dependant manner (97).
Regarding tumor cell metastasis, in vitro assays have shown
a direct ability of IL-33 to stimulate migration and invasion
of the lung cancer cell line A549 (98). Moreover, Andersson
and colleagues recently demonstrated that in mouse and human
fibroblast-rich pancreatic cancers, genetic deletion of IL-33, ST2
or MMP-9 markedly blocked metastasis (99). This appeared to
be due, in part, to modulation of the tumor microenvironment
by IL-33-producing CAFs, which caused the transition of tumor-
associated macrophages from an M1 (anti-tumorigenic) to an
M2 (pro-tumorigenic) phenotype. Moreover, the decoy receptor
sST2 has been found to have decreased expression in high-
metastatic cells compared with low-metastatic human andmouse
CRC cells (100). sST2 was found to negatively regulate tumor
growth and the metastatic spread of CRC through modification
of the tumor microenvironment. The expression of the IL-
33 receptor, ST2L, has also been implicated in metastasis
(101). Low-metastatic cells but not high-metastatic cells derived
from Lewis lung carcinoma were found to express functional
ST2L. IL-33 was seen to augment the cell death of ST2L-
positive low-metastatic cells, but not of the ST2L-negative high-
metastatic cells, suggesting that IL-33 enhances lung cancer
progression by selecting for more malignant cells in the tumor
microenvironment. Combined these data indicate the potential
therapeutic benefit of blocking this pathway in tumorigenesis.
Tumor-Inhibiting Effects of IL-33
Alongside the above listed pro-tumorigenic roles ascribed to the
IL-33/ST2 pathway are several strands of evidence implicating
a divergent role for IL-33 in the inhibition of tumorigenesis.
Many reports focusing specifically on tumoral expression of IL-
33 and ST2 have reported decreasing expression of these proteins
with increasing tumor stage. In cervical intraepithelial neoplasia
(CIN) tissues, IL-33 protein and mRNA levels in cervical tissues
were significantly lower in severe CIN as compared to those
patients with mild or no CIN (102). Levels of IL-33 have also
been shown to negatively correlate with tumor stage in multiple
myeloma patients (103) and lung cancer patients (104). Our
laboratory also demonstrated that ST2L expression is decreased
in human CRC tissue as compared to adjacent non-tumor
tissue, with lower ST2L expression correlating with poorer
patient prognosis (105). A similar pattern of expression has
been demonstrated in metastases. IL-33 expression was shown
to be reduced in many carcinomas upon their transition to the
metastatic form of the disease (106). These authors described low
tumoral expression of IL-33 as an immune biomarker associated
with recurrent prostate and kidney renal clear cell carcinomas.
Taken together these studies indicate that downregulation of
the IL-33/ST2 axis in epithelial cells is tightly associated with
tumorigenesis and metastasis, suggesting that retaining IL-
33/ST2 expression in these cells might inhibit cancer progression.
A key theme emerging in the field of the anti-tumorigenic
effects of IL-33 is the ability of Il-33 to induce Type 1 immune
responses. Given the fact that the focus of IL-33/ST2 research
was, for many years, related to its expression and involvement
in type 2 immune cells and responses, this is something of a
paradigm shift. Gao et al. investigated the effect of overexpressing
IL-33 in both B16 melanoma cells and 4T1 breast cancer cells
(107). Intradermal injection of these cells resulted in a greatly
decreased tumor growth rate. Characterization of immune cells
in the IL-33-expressing tumors revealed a local increase in
CD8+ T cells and NK cells, with increased expression of type 1
effectors such as IFN-y, IL-12 and granzyme B. Moreover, IL-
33 was shown to regulate local tumor-associated myeloid cells
and enhance the expression of MHC II as a result of the type I
immune response (108). Similarly, suppression of ST2 in colon
cancer cells was seen to enhance tumor growth and reduce CD8+
T cell infiltration into the tumors (105).
Administration of exogenous IL-33 has also been shown
to have potent tumor protective effects. Augmentation of the
immune response by systemic administration of recombinant
IL-33 was shown to inhibit leukemia growth and prolong the
survival of leukemia bearing mice (109). This was mediated via
an increase in CD8+ T cell and IFN-γ. Similarly, administration
of recombinant IL-33 inhibited the growth of established
melanoma tumors by activating myeloid dendritic cells and
tumor associated CD8+ T cells (110). Exogenous administration
of IL-33 has also been shown to limit cellular metastasis (111).
Injection of IL-33 into mice-bearing subcutaneous B16-F10
melanoma cells resulted not only in significant attenuation of
primary tumor growth but also in a reduction in pulmonary
metastasis. Finally, introduction of IL-33 into metastatic tumors
reduced the levels of circulating tumor cells and boosted
immune recognition against metastatic tumors in vivo (106).
Collectively, these data indicate that when high levels of IL-33
are administered, potent anti-tumor effects are observed.
Taken together, there can be no doubt that whilst IL-33 drives
tumorigenesis in certain cancers and cell types much caution
must be exerted surrounding future development of this cytokine
as a therapeutic target.
INTERLEUKIN-36
The IL-36 cytokines are a recently described subset of
the IL-1 family of cytokines (112). The three members of
this family, IL-36α, IL-36β, and IL-36γ, all share the same
receptor complex, which is composed of the IL-36 receptor
(IL36R/IL1RRP2/IL1RL1) and the IL1 Receptor accessory
protein. A biological inhibitor to this complex has also been
identified, the IL-36R antagonist (IL-36Ra). The IL-36 cytokines
and their receptor are expressed by several tissues, particularly
the lung, skin and intestine, as well as by immune cells such as
monocytes, macrophages, dendritic cells and T cells (112, 113).
Activity of the IL-36 cytokines relies on proteolytic cleavage, with,
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proteases released by neutrophils, in particular cathepsin G and
elastase, recently identified shown to be potent activators of the
IL-36 cytokines (114).
Similar to other IL-1 family members, IL-36 cytokines are
important activators of the inflammatory response, stimulating
both innate and adaptive immune responses (113). Whilst
these cytokines have been shown to play an important role
in autoimmune diseases, in particular in the pathogenesis of
psoriasis and Inflammatory Bowel Diseases, few studies to date
have investigated their role in cancer. Indeed, the majority
of studies to date have focused on IL-36γ, with few, if any,
investigating the role of IL-36α or IL-36β in cancer.
Tumor-Inhibiting Effects of IL-36
One of the first studies identifying a role for IL-36γ in
cancer determined that IL-36γ was anti-tumorigenic in breast
cancer and melanoma (115). In particular, IL-36γ was shown
to enhance the effector functions of CD8+ T cells, NK cells
and γδ T cells, to transform the tumor microenvironment
into one favoring tumor destruction, and ultimately to have
profound anti-tumor effects, suppressing both tumor growth and
metastasis. Chen et al. investigated this anti-tumorigenic role
of IL-36γ (116). The group developed and showed a polymer-
based delivery system that allowed the co-delivery of IL-36γ
expression plasmid with doxorubicin (Dox). This showed that
micelles loaded with IL-36γ and Dox significantly reduced the
metastatic spread of breast cancer cells to the lung. This was
associated with an enhanced type I immune response together
with a reduction in the levels of immunosuppressive myeloid-
derived suppressor cells in the lung. Moreover, injection of
bioactive IL-36γ into the tumor microenvironment was also
shown to delay tumor progression (117), via with the rapid
recruitment of T cells and the formation of tertiary lymphoid
organs (TLOs). TLOs form at sites of persistent inflammation
and provide a specialized microenvironment for priming of
naïve T cell into effector cells, with the presence of TLOs in a
broad range of cancer types associated with improved clinical
prognosis (118).
Subsequent studies in human colon cancer demonstrated
the presence of IL-36γ in a variety of cell types within the
tumor microenvironment, including immune cells, in particular
in classically activated or M1 macrophages, tumor cells and
vascular/perivascular cells (119). Interestingly, expression of the
IL-36 receptor antagonist, IL-36RN, was associated with elevated
expression of immune checkpoint molecules such as PD-1, PD-
L1, and CTLA-4 which are well-characterized inhibitors of the
anti-tumor immune response. Given that the binding affinity of
IL-36γ to the IL-36R is ∼ 100–1000-fold greater than IL-36RN,
the ability of exogenously administered IL-36γ to augment the
anti-tumor immune response and suppress tumor growth, may
be, in part, due to a reversal in suppression mediated by these
checkpoint inhibitors.
Of the remaining members of this family, IL-36α and IL-
36β, to date, three studies in the literature have suggested
that IL-36α may also have tumor-suppressive effects. IL-36α
was shown to suppress the growth of ovarian cancer cells
(120). Moreover, reduced expression of IL-36α has also been
shown to be associated with poor prognosis in colon (121)
and hepatocellular cancer (122). However, the mechanisms
underlying this suppressive function are unknown. As such, the
role of IL-36α or IL-36β in cancer remains poorly defined.
Interestingly, in contrast to other members of this family, to
the best of our knowledge, no studies to date have determined
that any of the IL-36 cytokines have tumor-promoting effects.
Given the paucity of studies concerning IL-36α and IL-36β in
tumorigenesis, further work is required to delineate the role
of these family members in cancer and future studies may
identify alternate tumor promoting effects of these cytokines. The
known functions of IL-36 signaling in cancer are summarized
in Figure 2.
INTERLEUKIN-37
Similar to IL-1α and IL-33, IL-37 is a dual-function cytokine
that can function as either a nuclear transcription factor or can
activate signaling pathways by binding to its receptor on the
cell surface (123, 124). The gene for IL-37 undergoes alternative
splicing, resulting in the expression of five splice variants (IL-
37a–e), although IL-37c and IL-37e are thought to encode non-
functional proteins (123). IL-37b is the most abundant and
most studied isoform, with almost all experimental published
investigations focused on this isoform (124).
Expression of IL-37 is induced by pro-inflammatory stimuli,
with IL-37 being synthesized as a precursor that is cleaved in
the cytosol by caspase-1, generating mature IL-37. Both the
precursor and mature forms are secreted by cells, and both
forms are biologically active (124). Extracellular IL-37 binds to
IL-18 receptor α (IL-18Rα; also used by IL-18), and recruits
IL-1 receptor 8 (IL-1R8/TIR-8/SIGIRR) for the activation of
intracellular signaling pathways, while the intracellular mature
form of IL-37 binds to SMAD-3 in the cytoplasm, and then
traffics to the nucleus. In contrast to the inflammatory function
seen with other IL-1 family members, IL-37 is consistently an
anti-inflammatory cytokine, with both extracellular and nuclear
IL-37 functioning to suppress innate and adaptive immune
responses by inhibiting the production of pro-inflammatory
cytokines and chemokines (125, 126).
Tumor-Promoting Effects of IL-37
While most studies investigating a role for IL-37 in cancer
have determined that IL-37 is an anti-tumorigenic cytokine,
some studies have suggested that IL-37 may also have pro-
tumorigenic functions. Consistent with a role in tumor growth
and metastasis, high levels of IL-37 in the serum of patients
with ovarian cancer was associated with poor prognosis, poor
overall survival and the progression-free survival (127). Similarly,
IL-37 protein expression was shown to be increased during the
malignant transformation of the oral mucosa, being elevated to
precancerous lesions as well as in OSCC (128). However, IL-37
expression was lower in OSCC cells with lymph node metastasis
than in those without metastasis, suggesting that IL-37may play a
role in cellular transformation, but once cells become malignant,
IL-37 functions to inhibit the tumorigenic process.
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FIGURE 2 | IL-36 Signaling in cancer. IL-36 signaling is achieved through binding of the IL-36α, IL-36β or IL-36γ cytokines to the IL-36 Receptor (IL1RL2), along with
the transmembrane accessory protein, IL-1RAcP. This binding may be inhibited through competitive binding of IL-36RA or IL-38. Agonist binding is followed by
subsequent engagement and phosphorylation of intracellular signaling molecules to activate transcription factors such as NF-κB and AP-1. This promotes the
observed anti-tumorigenic phenotype, which may be achieved by increased IFN-γ production, reduced immunosuppression and increased immune cell recruitment to
the local tumor microenvironment.
Moreover, a recent study determined that IL-37 is a
potent pro-angiogenic cytokine (129). IL-37 was shown to be
upregulated by endothelial cells under hypoxic conditions, and
to promote endothelial cell proliferation, capillary formation,
migration and vessel sprouting from aortic rings. Given
that tumor growth and metastasis depends on angiogenesis,
the ability of IL-37 to promote the formation of new
blood vessels in hypoxia regions of tumors could represent
an important pro-tumorigenic function for IL-37. However,
whether IL-37 functions as a pro-angiogenic factor in tumors is
currently unknown.
Tumor-Inhibiting Effects of IL-37
Given its ability to suppress the production of inflammatory
factors, it is unsurprising that themajority of studies investigating
the role of IL-37 in cancer have shown that IL-37 is
decreased in cancer, with low levels associated with poor
prognosis (130–133). Moreover, studies have determined that
IL-37 can suppress tumor progression, migration, invasion and
metastasis in multiple cancer types, including fibrosarcoma
(134), hepatocellular carcinoma (HCC)(135), cervical cancer
(136), lung cancer (137) and colon cancer (138). Consistent with
these studies, intratumoral injection of IL-37 or over-expression
of IL-37 by tumor cells inhibited tumor growth (130, 132, 134).
Several mechanisms have been proposed, including suppression
of STAT3 signaling (130, 136, 137). Activated STAT3 is known
to increased cell proliferation and invasion, and to promote
oncogenic inflammation, with IL-37 shown to inhibit both the
expression and phosphorylation of STAT3. IL-37 has also been
shown to inhibit epithelial-mesenchymal transition (137, 139,
140), which plays an important role in metastasis. Additional
mechanisms proposed for the anti-metastatic function include
inhibition of Rac1 activation (133), with the intracellular mature
form of IL-37, but not its extracellular form, markedly inhibiting
the migration of multiple tumor types.
IL-37 has also been shown to affect immune cell recruitment to
the tumor microenvironment (132). IL-37 expression positively
correlated with the density of tumor infiltrating CD57+ NK cells
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in HCC tumors, which were significantly associated with better
overall survival in HCC patients. Moreover, overexpression of
IL-37 by hepatic tumor cells resulted in enhanced local CD57+
NK cell infiltration of the tumors and suppressed tumor growth
in vivo (132). This relationship between high intratumoral
levels of NK cells and increased survival has been shown in
several cancer types (141). Moreover, given that IL-37 suppresses
inflammatory cytokine production, IL-37 could potentially alter
TABLE 1 | Pro- and anti-tumorigenic functions of IL-1 family members in cancer.








Pancreatic cancer (19), Lung cancer (14)
ALL (16)
Breast cancer (13)
HNSCC (11), Gastric Cancer (12), Pancreatic cancer (17, 19),
Breast cancer (21)
Pancreatic cancer (19), Breast Cancer (21, 22)
Pancreatic cancer (17), Fibrosarcoma (18)
Anti-tumorigenic Immune cell recruitment
Proliferation
Fibrosarcoma (25), lymphoma (26)






Fibrosarcoma (32), Lung cancer (34), Pancreatic cancer (35),
Melanoma (36), Breast cancer (38)
Fibrosarcoma (32)
Breast cancer (37–39), Lung cancer (45), CRC (50)
Breast cancer (38), Fibrosarcoma (32)
Breast cancer (37)
Anti-tumorigenic Immune cell recruitment
Metastasis







Melanoma (61, 62), HCC (55)
Melanoma (64, 65, 67), Colon Carcinoma (64, 65)
Myeloma (66)
HCC (61), Breast cancer (63)
Anti-tumorigenic Immune cell modulation Melanoma (70, 71, 78), CRC7 (3), Lung cancer (74), Myeloid
leukaemia (75), Ovarian Cancerm (76), Breast Cancer (79)





OSCC (96), Colon cancer (97), CRC (98, 101)
Breast Cancer (91), HNSCC (95), Pancreatic Cancer (92), Cervical
Cancer (92)
Lung Cancer (86, 99, 102), Breast cancer (89–91), Ovarian Cancer
(87), CRC (88, 101)
HNSCC (95), Lung Cancer (99)




Cervical Cancer (103) Multiple Myeloma (104), Lung Cancer (105),
CRC (106), Melanoma (108, 111), Breast Cancer (108)
Prostate Cancer (107), Renal Clear Cell Carcinoma (107)




Breast Cancer (116, 117), Melanoma (116), Fibrosarcoma (118),
Colon cancer (118, 120)








Renal Cell Carcinoma (132), HCC (133, 136), Fibrosarcoma (135),
Colon Cancer (139)
Cervical Cancer (137), Lung Cancer (140),
Cervical Cancer (131, 137), Lung cancer (131, 134, 138),
Gallbladder Cancer (141), Breast Cancer (131), Liver
adenocarcinoma (131), Prostate Cancer (131)
Lung Cancer (140), Gallbladder cancer (141), OSCC (123)
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the tumor microenvironment in favor of one that promotes
tumor rejection. For instance, IL-37 reduces the secretion by both
immune cells (142) and tumor cells (133) of IL-6, IL-1β and
tumor necrosis factor alpha, cytokines known to play a role in
tumor progression.
Finally, consistent with IL-37b being the most
abundant isoform of IL-37, studies investigating tumor
expression of the IL-37 splice variants identified
IL-37b as the isoform expressed by breast, liver,
lung and prostate cancer, with low levels of IL-37b
significantly associated with poor prognosis (130).
Whether this variant of IL-37 is important in suppressing
tumor growth and metastasis in all forms of cancer
is unknown.
Taken together, the major function of this member of the IL-1
family is to suppress the development and growth of tumor cells,
and suggest that it represents a novel target for the treatment of
neoplastic disease.
INTERLEUKIN-38
IL-38 is the most recent member of the IL-1 family to be
identified. It was discovered by two independent research groups
in 2001 (143, 144). IL-38 shares structural features with both IL-
1Ra and IL-36Ra, suggesting that it might act as an IL-1 family
antagonist. Indeed, one of the first described biological functions
of IL-38 was blocking the activation of the IL-36R, similar to that
of IL-36Ra (145). In addition to binding to the IL-36R, studies
have also proposed that IL-38 can bind to IL-1R1, or can interact
with one of the inhibitory co-receptors of the IL-1R family,
namely SIGIRR, TIGIRR1 and/or TIGIRR2 (146, 147). Similar
to other family members, IL-38 is also processed by proteolytic
cleavage, although there is currently a lack of consensus on the
cleavage site.
IL-38 is expressed in several tissues including tonsils,
placenta, heart and brain, and has been implicated in a
variety of diseases including cardiovascular and autoimmune
disease. In general, IL-38 polymorphisms are associated with
increased susceptibility for auto-inflammatory diseases such as
spondyloarthritis, rheumatoid arthritis, and psoriatic arthritis,
suggesting a role of IL-38 suppressing chronic inflammation
(147). Consistent with this, overexpression of IL-38 attenuated
the severity of experimental arthritis, in part by decreasing the
production of pro-inflammatory cytokines by macrophages and
synovial fibroblasts (148).
Tumor-Promoting Effects of IL-38
Few studies to date have investigated the role of IL-38 in
cancer. One of the first studies investigating expression of
IL-38 in cancer demonstrated that tumor expression of IL-
38 was increased in multiple cancer types, and that high
expression of IL-38 was associated with poor prognosis in lung
adenocarcinoma (149).
Tumor-Inhibiting Effects of IL-38
In contrast, Wang et al. demonstrated that IL-38 expression
is decreased in NSCLC alone relative to adjacent non-
tumor tissue (150), with lack of IL-38 expression correlating
with poor prognosis. Administration of recombinant IL-38
inhibited β-catenin expression and reduced the proliferation,
migration and invasion of lung cancer cells in vitro, while
increasing cell death. Consistent with a role for IL-38 in
suppressing lung cancer, overexpression of IL-38 suppressed
NSCLC development in vivo and increased the sensitivity to
chemotherapeutic drugs. The reason for these divergent results
is unclear, but may be due to differential processing of the
precursor form of IL-38 by the different tumor types. Studies
comparing the function of full-length IL-38 vs. truncated IL-
38 in macrophages (151) demonstrated that high concentrations
of the truncated form decreased IL-1β-induced IL-6 production
in macrophages. However, the full-length form of IL-38
increased IL-6 production at these concentrations, suggesting the
biological function of IL-38 is affected by processing in vivo.
Although IL-38 is well characterized as an anti-inflammatory
cytokine (147), the role of IL-38 in cancer remains to
be determined.
CONCLUSIONS
The IL-1 superfamily is a diverse family of cytokines, most of
whose members have been shown to have dual functions in
tumorigenesis with both pro- and anti-tumorigenic roles being
ascribed (Table 1). The role of these cytokines varies greatly
depending on the tissues and organs involved, the inflammatory
background and the stage of the cancer. An additional factor
determining the pro- or anti- tumorigenic effects of these
cytokines appears to be whether the cytokines are produced
by the tumor-infiltrating immune populations or by the tumor
cells. Finally, it is possible that the levels of the cytokines
present within the tumor microenvironment may have a role
in determining the outcome of the effect on tumorigenesis. For
example, when the pro-inflammatory cytokines are produced
at persistent, chronic low levels, often by the tumor itself,
this could play a role in shaping an immune-suppressive
tumor microenvironment, facilitating a chronic inflammatory
state and enabling tumor growth and spread. In line with
this, results from the CANTOS trial imply that suppressing
such chronic inflammatory effects of these cytokines over an
extended periodmay have significant benefits in terms of limiting
cancer development and progression. In contrast, exogenous
administration of high levels of these cytokines has been shown
to often have a potent anti-tumorigenic effect due to recruitment
and activation of Type 1 immune responses. Further work is
required in this field to determine the levels of these cytokines
within both normal and tumor tissue.
There is clear potential for the development of agents
to target these cytokines, whose administration, most likely
as a combination therapy with checkpoint inhibitor proteins,
will activate the anti-tumor immune response and lead to
tumor regression. Given the complexity and the dual functions
associated with these proteins, the development of these
cytokines as therapeutic agents will require extensive knowledge
and understanding of the specific functions of each member of
this family in each individual cancer type. Finally further work
regarding the more novel members of this family is required to
firmly establish their role in tumor development and progression.
Frontiers in Immunology | www.frontiersin.org 11 June 2019 | Volume 10 | Article 1197
Baker et al. IL-1 Family Members in Cancer
AUTHOR CONTRIBUTIONS
All authors listed have made a substantial, direct and intellectual
contribution to the work, and approved it for publication.
FUNDING
KJB is funded through Government of Ireland Irish Research
Council grant (GOIPG/2018/2974).
REFERENCES
1. Coussens LM, Werb Z. Inflammation and cancer. Nature. (2002) 420:860–7.
doi: 10.1038/nature01322
2. Hanahan D, Coussens LM. Accessories to the crime: functions of cells
recruited to the tumor microenvironment. Cancer Cell. (2012) 21:309–22.
doi: 10.1016/j.ccr.2012.02.022
3. Hanahan D, and Weinberg RA. Hallmarks of cancer: the next generation.
Cell. (2011) 144:646–74. doi: 10.1016/j.cell.2011.02.013
4. Marshall EA, Ng KW, Kung SH, Conway EM, Martinez VD, Halvorsen
EC, et al. Emerging roles of T helper 17 and regulatory T cells
in lung cancer progression and metastasis. Mol Cancer. (2016) 15:67.
doi: 10.1186/s12943-016-0551-1
5. Shalapour S, Karin M. Immunity, inflammation, and cancer: an eternal
fight between good and evil. J Clin Invest. (2015) 125:3347–3355.
doi: 10.1172/JCI80007
6. Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to
the future. Immunity. (2013) 39:1003–18. doi: 10.1016/j.immuni.2013.11.010
7. Weber A, Wasiliew P, Kracht M. Interleukin-1 (IL-1) pathway. Sci Signal.
(2010) 3:cm1. doi: 10.1126/scisignal.3105cm1
8. Rider P, Carmi Y, Voronov E, Apte RN. Interleukin-1alpha. Semin Immunol.
(2013) 25:430–8. doi: 10.1016/j.smim.2013.10.005
9. Mosley B, Dower SK, Gillis S, Cosman D. Determination of the minimum
polypeptide lengths of the functionally active sites of human interleukins
1 alpha and 1 beta. Proc Natl Acad Sci USA. (1987) 84:4572–6.
doi: 10.1073/pnas.84.13.4572
10. Mantovani A, Barajon I, Garlanda C. IL-1 and IL-1 regulatory pathways
in cancer progression and therapy. Immunol Rev. (2018) 281:57–61.
doi: 10.1111/imr.12614
11. Leon X, Bothe C, Garcia J, Parreno M, Alcolea S, Quer M, et al.
Expression of IL-1alpha correlates with distant metastasis in patients with
head and neck squamous cell carcinoma. Oncotarget. (2015) 6:37398–409.
doi: 10.18632/oncotarget.6054
12. Tomimatsu S, Ichikura T, Mochizuki H. Significant
correlation between expression of interleukin-1alpha and liver
metastasis in gastric carcinoma. Cancer. (2001) 91:1272–6.
doi: 10.1002/1097-0142(20010401)91:7<1272::AID-CNCR1128>3.0.CO;2-Z
13. Singer CF, Hudelist G, Gschwantler-Kaulich D, Fink-Retter A, Mueller
R, Walter I, et al. Interleukin-1alpha protein secretion in breast
cancer is associated with poor differentiation and estrogen receptor
alpha negativity. Int J Gynecol Cancer. (2006) 16(Suppl 2):556–9.
doi: 10.1111/j.1525-1438.2006.00695.x
14. Watari K, Shibata T, Kawahara A, Sata K, Nabeshima H, Shinoda A, et al.
Tumor-derived interleukin-1 promotes lymphangiogenesis and lymph node
metastasis through M2-type macrophages. PLoS ONE. (2014) 9:e99568.
doi: 10.1371/journal.pone.0099568
15. Charbonneau B, Block MS, Bamlet WR, Vierkant RA, Kalli KR, Fogarty
Z, et al. Risk of ovarian cancer and the NF-kappaB pathway: genetic
association with IL1A and TNFSF10. Cancer Res. (2014) 74:852–61.
doi: 10.1158/0008-5472.CAN-13-1051
16. Zhang Y, Yu X, Lin D, Lei L, Hu B, Cao F, et al. Propiece IL-1alpha
facilitates the growth of acute T-lymphocytic leukemia cells through
the activation of NF-kappaB and SP1. Oncotarget. (2017) 8:15677–88.
doi: 10.18632/oncotarget.14934
17. Melisi D, Niu J, Chang Z, Xia Q, Peng B, Ishiyama S, et al. Secreted
interleukin-1alpha induces a metastatic phenotype in pancreatic cancer by
sustaining a constitutive activation of nuclear factor-kappaB.Mol Cancer Res.
(2009) 7:624–33. doi: 10.1158/1541-7786.MCR-08-0201
18. Tjomsland V, Spangeus A, Valila J, Sandstrom P, Borch K, Druid H,
et al. Interleukin 1alpha sustains the expression of inflammatory factors in
human pancreatic cancer microenvironment by targeting cancer-associated
fibroblasts. Neoplasia. (2011) 13:664–75. doi: 10.1593/neo.11332
19. Xu D, Matsuo Y, Ma J, Koide S, Ochi N, Yasuda A, et al. Cancer cell-
derived IL-1alpha promotes HGF secretion by stromal cells and enhances
metastatic potential in pancreatic cancer cells. J Surg Oncol. (2010) 102:469–
77. doi: 10.1002/jso.21530
20. Elkabets M, Krelin Y, Dotan S, Cerwenka A, Porgador A, Lichtenstein
RG, et al. Host-derived interleukin-1alpha is important in determining the
immunogenicity of 3-methylcholantrene tumor cells. J Immunol. (2009)
182:4874–81. doi: 10.4049/jimmunol.0803916
21. Kuan EL, Ziegler SF. A tumor-myeloid cell axis, mediated via the cytokines
IL-1alpha and TSLP, promotes the progression of breast cancer. Nat
Immunol. (2018) 19:366–74. doi: 10.1038/s41590-018-0066-6
22. Liu S, Lee JS, Jie C, Park MH, Iwakura Y, Patel Y, et al. HER2
overexpression triggers an il1alpha proinflammatory circuit to drive
tumorigenesis and promote chemotherapy resistance. Cancer Res. (2018)
78:2040–51. doi: 10.1158/0008-5472.CAN-17-2761
23. Hong DS, Hui D, Bruera E, Janku F, Naing A, Falchook GS, et al. MABp1, a
first-in-class true human antibody targeting interleukin-1alpha in refractory
cancers: an open-label, phase 1 dose-escalation and expansion study. Lancet
Oncol. (2014) 15:656–66. doi: 10.1016/S1470-2045(14)70155-X
24. Hickish T, Andre T, Wyrwicz L, Saunders M, Sarosiek T, Kocsis J, et al.
MABp1 as a novel antibody treatment for advanced colorectal cancer: a
randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol.
(2017) 18:192–201. doi: 10.1016/S1470-2045(17)30006-2
25. Kurzrock R, Hickish T, Wyrwicz L, Saunders M, Wu Q, Stecher
M, et al. Interleukin-1 receptor antagonist levels predict favorable
outcome after bermekimab, a first-in-class true human interleukin-1alpha
antibody, in a phase III randomized study of advanced colorectal
cancer. Oncoimmunology. (2019) 8:1551651. doi: 10.1080/2162402X.2018
.1551651
26. Douvdevani A, Huleihel M, Zoller M, Segal S, Apte RN. Reduced
tumorigenicity of fibrosarcomas which constitutively generate IL-1 alpha
either spontaneously or following IL-1 alpha gene transfer. Int J Cancer.
(1992) 51:822–30. doi: 10.1002/ijc.2910510526
27. Voronov E, Weinstein Y, Benharroch D, Cagnano E, Ofir R, Dobkin
M, et al. Antitumor and immunotherapeutic effects of activated invasive
T lymphoma cells that display short-term interleukin 1alpha expression.
Cancer Res. (1999) 59:1029–35.
28. Sgagias MK, Kasid A, Danforth DN, Jr. Interleukin-1 alpha and tumor
necrosis factor-alpha (TNF alpha) inhibit growth and induce TNFmessenger
RNA in MCF-7 human breast cancer cells.Mol Endocrinol. (1991) 5:1740–7.
doi: 10.1210/mend-5-11-1740
29. Maund SL, Barclay WW, Hover LD, Axanova LS, Sui G, Hipp JD,
et al. Interleukin-1alpha mediates the antiproliferative effects of 1,25-
dihydroxyvitamin D3 in prostate progenitor/stem cells. Cancer Res. (2011)
71:5276–86. doi: 10.1158/0008-5472.CAN-10-2160
30. Maund SL, Shi L, Cramer SD. A role for interleukin-1 alpha in the. (2013)
1,25 dihydroxyvitamin D3 response in mammary epithelial cells. PLoS ONE
8:e81367. doi: 10.1371/journal.pone.0081367
31. Dagenais M, Dupaul-Chicoine J, Douglas T, Champagne C, Morizot A,
Saleh M. The Interleukin (IL)-1R1 pathway is a critical negative regulator
of PyMT-mediated mammary tumorigenesis and pulmonary metastasis.
Oncoimmunology. (2017) 6:e1287247. doi: 10.1080/2162402X.2017.1287247
32. Apte RN, Krelin Y, Song X, Dotan S, Recih E, Elkabets M, et al.
Effects of micro-environment- and malignant cell-derived interleukin-1 in
carcinogenesis, tumour invasiveness and tumour-host interactions. Eur J
Cancer. (2006) 42:751–9. doi: 10.1016/j.ejca.2006.01.010
33. Krelin Y, Voronov E, Dotan S, Elkabets M, Reich E, Fogel M, et al.
Interleukin-1beta-driven inflammation promotes the development and
Frontiers in Immunology | www.frontiersin.org 12 June 2019 | Volume 10 | Article 1197
Baker et al. IL-1 Family Members in Cancer
invasiveness of chemical carcinogen-induced tumors. Cancer Res. (2007)
67:1062–71. doi: 10.1158/0008-5472.CAN-06-2956
34. Nakao S, Kuwano T, Tsutsumi-Miyahara C, Ueda S, Kimura YN, Hamano S,
et al. Infiltration of COX-2-expressing macrophages is a prerequisite for IL-
1 beta-induced neovascularization and tumor growth. J Clin Invest. (2005)
115:2979–91. doi: 10.1172/JCI23298
35. Saijo Y, Tanaka M, Miki M, Usui K, Suzuki T, Maemondo M,
et al. Proinflammatory cytokine IL-1 beta promotes tumor growth
of Lewis lung carcinoma by induction of angiogenic factors: in vivo
analysis of tumor-stromal interaction. J Immunol. (2002) 169:469–75.
doi: 10.4049/jimmunol.169.1.469
36. Shchors K, Shchors E, Rostker F, Lawlor ER, Brown-Swigart L, Evan GI.
The Myc-dependent angiogenic switch in tumors is mediated by interleukin
1beta. Genes Dev. (2006) 20:2527–38. doi: 10.1101/gad.1455706
37. Carmi Y, Dotan S, Rider P, Kaplanov I, White MR, Baron R, et al. The role
of IL-1beta in the early tumor cell-induced angiogenic response. J Immunol.
(2013) 190:3500–9. doi: 10.4049/jimmunol.1202769
38. Guo B, Fu S, Zhang J, Liu B, Li Z. Targeting inflammasome/IL-1 pathways for
cancer immunotherapy. Sci Rep. (2016) 6:36107. doi: 10.1038/srep36107
39. Weichand B, Popp R, Dziumbla S, Mora J, Strack E, Elwakeel E, et al.
S1PR1 on tumor-associated macrophages promotes lymphangiogenesis
and metastasis via NLRP3/IL-1beta. J Exp Med. (2017) 214:2695–713.
doi: 10.1084/jem.20160392
40. Oh K, Lee OY, Park Y, Seo MW, Lee DS. IL-1beta induces IL-6 production
and increases invasiveness and estrogen-independent growth in a TG2-
dependent manner in human breast cancer cells. BMCCancer. (2016) 16:724.
doi: 10.1186/s12885-016-2746-7
41. Voigt C, May P, Gottschlich A, Markota A, Wenk D, Gerlach I, et al. Cancer
cells induce interleukin-22 production from memory CD4(+) T cells via
interleukin-1 to promote tumor growth. Proc Natl Acad Sci USA. (2017)
114:12994–9. doi: 10.1073/pnas.1705165114
42. Bent R, Moll L, Grabbe S, Bros M. Interleukin-1 beta-A friend or foe in
malignancies? Int J Mol Sci. (2018) 19:e2155. doi: 10.3390/ijms19082155
43. Kaplanov I, Carmi Y, Kornetsky R, Shemesh A, Shurin GV, Shurin MR, et al.
Blocking IL-1beta reverses the immunosuppression in mouse breast cancer
and synergizes with anti-PD-1 for tumor abrogation. Proc Natl Acad Sci USA.
(2019) 116:1361–9. doi: 10.1073/pnas.1812266115
44. Lust JA, Lacy MQ, Zeldenrust SR, Dispenzieri A, Gertz MA, Witzig TE, et al.
Induction of a chronic disease state in patients with smoldering or indolent
multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6
production and the myeloma proliferative component. Mayo Clin Proc.
(2009) 84:114–22. doi: 10.4065/84.2.114
45. Wu TC, Xu K, Martinek J, Young RR, Banchereau R, George J, et al.
IL1 Receptor antagonist controls transcriptional signature of inflammation
in patients with metastatic breast cancer. Cancer Res. (2018) 78:5243–58.
doi: 10.1158/0008-5472.CAN-18-0413
46. Dinarello CA. An Interleukin-1 signature in breast cancer treated
with interleukin-1 receptor blockade: implications for treating cytokine
release syndrome of checkpoint inhibitors. Cancer Res. (2018) 78:5200–2.
doi: 10.1158/0008-5472.CAN-18-2225
47. North RJ, Neubauer RH, Huang JJ, Newton RC, Loveless SE. Interleukin
1-induced, T cell-mediated regression of immunogenic murine tumors.
requirement for an adequate level of already acquired host concomitant
immunity. J Exp Med. (1988) 168:2031–43. doi: 10.1084/jem.168.6.2031
48. Haabeth OA, Lorvik KB, Hammarstrom C, Donaldson IM, Haraldsen G,
Bogen B, et al. Inflammation driven by tumour-specific Th1 cells protects
against B-cell cancer. Nat Commun. (2011) 2:240. doi: 10.1038/ncomms1239
49. Haabeth OA, Lorvik KB, Yagita H, Bogen B, Corthay A. Interleukin-1
is required for cancer eradication mediated by tumor-specific Th1 cells.
Oncoimmunology. (2016) 5:e1039763. doi: 10.1080/2162402X.2015.1039763
50. Allen IC, TeKippe EM, Woodford RM, Uronis JM, Holl EK, Rogers AB,
et al. The NLRP3 inflammasome functions as a negative regulator of
tumorigenesis during colitis-associated cancer. J Exp Med. (2010) 207:1045–
56. doi: 10.1084/jem.20100050
51. Dmitrieva-Posocco O, Dzutsev A, Posocco DF, Hou V, Yuan W, Thovarai V,
et al. Cell-type-specific responses to interleukin-1 control microbial invasion
and tumor-elicited inflammation in colorectal cancer. Immunity. (2019)
50:166–80 e167. doi: 10.1016/j.immuni.2018.11.015
52. Castano Z, San Juan BP, Spiegel A, Pant A, DeCristo MJ, Laszewski T, et al.
IL-1beta inflammatory response driven by primary breast cancer prevents
metastasis-initiating cell colonization. Nat Cell Biol. (2018) 20:1084–97.
doi: 10.1038/s41556-018-0173-5
53. Li Y, Wang L, Pappan L, Galliher-Beckley A, Shi J. IL-1beta promotes
stemness and invasiveness of colon cancer cells through Zeb1 activation.Mol
Cancer. (2012) 11:87. doi: 10.1186/1476-4598-11-87
54. Nakamura K, Okamura H, Wada M, Nagata K, Tamura T. Endotoxin-
induced serum factor that stimulates gamma interferon production. Infect
Immun. (1989) 57:590–5.
55. Dinarello CA. Interleukin-18. Methods. (1999) 19:121–32.
doi: 10.1006/meth.1999.0837
56. Fabbi M, Carbotti G, Ferrini S. Context-dependent role of IL-18 in cancer
biology and counter-regulation by IL-18BP. J Leukoc Biol. (2015) 97:665–75.
doi: 10.1189/jlb.5RU0714-360RR
57. Tangkijvanich P, Thong-Ngam D, Mahachai V, Theamboonlers A,
Poovorawan Y. Role of serum interleukin-18 as a prognostic factor in
patients with hepatocellular carcinoma. World J Gastroenterol. (2007)
13:4345–9. doi: 10.3748/wjg.v13.i32.4345
58. Kawabata T, Ichikura T, Majima T, Seki S, Chochi K, Takayama E,
et al. Preoperative serum interleukin-18 level as a postoperative prognostic
marker in patients with gastric carcinoma. Cancer. (2001) 92:2050–5.
doi: 10.1002/1097-0142(20011015)92:8<2050::AID-CNCR1544>3.0.CO;2-5
59. Carbone A, Vizio B, Novarino A, Mauri FA, Geuna M, Robino C, et al.
IL-18 paradox in pancreatic carcinoma: elevated serum levels of free IL-
18 are correlated with poor survival. J Immunother. (2009) 32:920–31.
doi: 10.1097/CJI.0b013e3181b29168
60. Kang JS, Bae SY, Kim HR, Kim YS, Kim DJ, Cho BJ, et al. Interleukin-
18 increases metastasis and immune escape of stomach cancer via the
downregulation of CD70 and maintenance of CD44. Carcinogenesis. (2009)
30:1987–96. doi: 10.1093/carcin/bgp158
61. Kim KE, Song H, Hahm C, Yoon SY, Park S, Lee HR, et al.
Expression of ADAM33 is a novel regulatory mechanism in IL-18-
secreted process in gastric cancer. J Immunol. (2009) 182:3548–55.
doi: 10.4049/jimmunol.0801695
62. Kim KE, Song H, Kim TS, Yoon D, Kim CW, Bang SI, et al. Interleukin-
18 is a critical factor for vascular endothelial growth factor-enhanced
migration in human gastric cancer cell lines. Oncogene. (2007) 26:1468–76.
doi: 10.1038/sj.onc.1209926
63. Carrascal MT,Mendoza L, Valcarcel M, Salado C, Egilegor E, Telleria N, et al.
Interleukin-18 binding protein reduces b16 melanoma hepatic metastasis
by neutralizing adhesiveness and growth factors of sinusoidal endothelium.
Cancer Res. (2003) 63:491–7.
64. Valcarcel M, Carrascal T, Crende O, Vidal-Vanaclocha F. IL-18
regulates melanoma VLA-4 integrin activation through a Hierarchized
sequence of inflammatory factors. J Invest Dermatol. (2014) 134:470–80.
doi: 10.1038/jid.2013.342
65. Yang Y, Cheon S, Jung MK, Song SB, Kim D, Kim HJ, et al. Interleukin-18
enhances breast cancer cell migration via down-regulation of claudin-12 and
induction of the p38 MAPK pathway. Biochem Biophys Res Commun. (2015)
459:379–86. doi: 10.1016/j.bbrc.2015.02.108
66. Terme M, Ullrich E, Aymeric L, Meinhardt K, Desbois M, Delahaye N, et al.
IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Res.
(2011) 71:5393–9. doi: 10.1158/0008-5472.CAN-11-0993
67. Terme M, Ullrich E, Aymeric L, Meinhardt K, Coudert JD, Desbois M, et al.
Cancer-induced immunosuppression: IL-18-elicited immunoablative NK
cells. Cancer Res. (2012) 72:2757–67. doi: 10.1158/0008-5472.CAN-11-3379
68. Nakamura K, Kassem S, Cleynen A, Chretien ML, Guillerey C, Putz
EM, et al. Dysregulated IL-18 is a key driver of immunosuppression
and a possible therapeutic target in the multiple myeloma
microenvironment. Cancer Cell. (2018) 33:634–48 e635. doi: 10.1016/j.ccell.
2018.02.007
69. Lim HX, Hong HJ, Cho D, Kim TS. IL-18 enhances immunosuppressive
responses by promoting differentiation into monocytic myeloid-
derived suppressor cells. J Immunol. (2014) 193:5453–60.
doi: 10.4049/jimmunol.1401282
70. Tarhini AA, Millward M, Mainwaring P, Kefford R, Logan T, Pavlick A,
et al. A phase 2, randomized study of SB-485232, rhIL-18, in patients
Frontiers in Immunology | www.frontiersin.org 13 June 2019 | Volume 10 | Article 1197
Baker et al. IL-1 Family Members in Cancer
with previously untreated metastatic melanoma. Cancer. (2009) 115:859–68.
doi: 10.1002/cncr.24100
71. Robertson MJ, Kline J, Struemper H, Koch KM, Bauman JW, Gardner
OS, et al. A dose-escalation study of recombinant human interleukin-18
in combination with rituximab in patients with non-Hodgkin lymphoma.
J Immunother. (2013) 36:331–41. doi: 10.1097/CJI.0b013e31829d7e2e
72. Osaki T, Peron JM, Cai Q, Okamura H, Robbins PD, Kurimoto M, et al. IFN-
gamma-inducing factor/IL-18 administration mediates IFN-gamma- and
IL-12-independent antitumor effects. J Immunol. (1998) 160:1742–9.
73. Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K. Natural cytotoxic
activity of peripheral-blood lymphocytes and cancer incidence: an 11-
year follow-up study of a general population. Lancet. (2000) 356:1795–9.
doi: 10.1016/S0140-6736(00)03231-1
74. Coca S, Perez-Piqueras J, Martinez D, Colmenarejo A, Saez MA,
Vallejo C, et al. The prognostic significance of intratumoral natural
killer cells in patients with colorectal carcinoma. Cancer. (1997)
79:2320–8. doi: 10.1002/(SICI)1097-0142(19970615)79:12&lt;2320::AID-
CNCR5&gt;3.0.CO;2-P
75. Villegas FR, Coca S, Villarrubia VG, Jimenez R, Chillon MJ, Jareno J, et al.
Prognostic significance of tumor infiltrating natural killer cells subset CD57
in patients with squamous cell lung cancer. Lung Cancer. (2002) 35:23–8.
doi: 10.1016/S0169-5002(01)00292-6
76. Romee R, Rosario M, Berrien-Elliott MM, Wagner JA, Jewell BA, Schappe
T, et al. Cytokine-induced memory-like natural killer cells exhibit enhanced
responses against myeloid leukemia. Sci Transl Med. (2016) 8:357ra123.
doi: 10.1126/scitranslmed.aaf2341
77. Uppendahl LD, Felices M, Bendzick L, Ryan C, Kodal B, Hinderlie P, et al.
Cytokine-induced memory-like natural killer cells have enhanced function,
proliferation, and in vivo expansion against ovarian cancer cells. Gynecol
Oncol. (2019) 153:149–57. doi: 10.1016/j.ygyno.2019.01.006
78. Ni J, Miller M, Stojanovic A, Garbi N, Cerwenka A. Sustained effector
function of IL-12/15/18-preactivated NK cells against established tumors. J
Exp Med. (2012) 209:2351–65. doi: 10.1084/jem.20120944
79. Choi IK, Lee JS, Zhang SN, Park J, Sonn CH, Lee KM, et al.
Oncolytic adenovirus co-expressing IL-12 and IL-18 improves tumor-
specific immunity via differentiation of T cells expressing IL-12Rbeta2 or
IL-18Ralpha. Gene Ther. (2011) 18:898–909. doi: 10.1038/gt.2011.37
80. Loeffler M, Le’Negrate G, Krajewska M, Reed JC. IL-18-producing
Salmonella inhibit tumor growth. Cancer Gene Ther. (2008) 15:787–94.
doi: 10.1038/cgt.2008.48
81. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al.
IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related
protein ST2 and induces T helper type 2-associated cytokines. Immunity.
(2005) 23:479–90. doi: 10.1016/j.immuni.2005.09.015
82. Hayakawa H, Hayakawa M, Kume A, Tominaga S. Soluble ST2 blocks
interleukin-33 signaling in allergic airway inflammation. J Biol Chem. (2007)
282:26369–80. doi: 10.1074/jbc.M704916200
83. Takatori H, Makita S, Ito T, Matsuki A, Nakajima H. Regulatory mechanisms
of IL-33-ST2-mediated allergic inflammation. Front Immunol. (2018) 9:2004.
doi: 10.3389/fimmu.2018.02004
84. Millar NL, O’Donnell C, McInnes IB, Brint E. Wounds that heal
and wounds that don’t - the role of the IL-33/ST2 pathway in
tissue repair and tumorigenesis. Semin Cell Dev Biol. (2017) 61:41–50.
doi: 10.1016/j.semcdb.2016.08.007
85. Wasmer MH, Krebs P. The role of IL-33-dependent inflammation
in the tumor microenvironment. Front Immunol. (2016) 7:682.
doi: 10.3389/fimmu.2016.00682
86. Yang ZP, Ling DY, Xie YH, Wu WX, Li JR, Jiang J, et al. The Association of
serum IL-33 and sST2 with breast cancer. Dis Markers. (2015) 2015:516895.
doi: 10.1155/2015/516895
87. Wang C, Chen Z, Bu X, Han Y, Shan S, Ren T, et al. IL-33 signaling
fuels outgrowth and metastasis of human lung cancer. Biochem Biophys Res
Commun. (2016) 479:461–8. doi: 10.1016/j.bbrc.2016.09.081
88. Tong X, Barbour M, Hou K, Gao C, Cao S, Zheng J, et al. Interleukin-
33 predicts poor prognosis and promotes ovarian cancer cell growth and
metastasis through regulating ERK and JNK signaling pathways.Mol Oncol.
(2016) 10:113–25. doi: 10.1016/j.molonc.2015.06.004
89. Maywald RL, Doerner SK, Pastorelli L, De Salvo C, Benton SM, Dawson EP,
et al. IL-33 activates tumor stroma to promote intestinal polyposis. Proc Natl
Acad Sci USA. (2015) 112:E2487–96. doi: 10.1073/pnas.1422445112
90. Jovanovic I, Radosavljevic G, Mitrovic M, Juranic VL, McKenzie AN,
Arsenijevic N, et al. ST2 deletion enhances innate and acquired immunity
to murine mammary carcinoma. Eur J Immunol. (2011) 41:1902–12.
doi: 10.1002/eji.201141417
91. Gillibert-Duplantier J, Duthey B, Sisirak V, Salaun D, Gargi T, Tredan O,
et al. Gene expression profiling identifies sST2 as an effector of ErbB2-driven
breast carcinoma cell motility, associated with metastasis. Oncogene. (2012)
31:3516–24. doi: 10.1038/onc.2011.525
92. Jovanovic IP, Pejnovic NN, Radosavljevic GD, Pantic JM, Milovanovic
MZ, Arsenijevic NN, et al. Interleukin-33/ST2 axis promotes breast
cancer growth and metastases by facilitating intratumoral accumulation
of immunosuppressive and innate lymphoid cells. Int J Cancer. (2014)
134:1669–82. doi: 10.1002/ijc.28481
93. Larsen KM, Minaya MK, Vaish V, Pena MMO. The role of IL-
33/ST2 pathway in tumorigenesis. Int J Mol Sci. (2018) 19:e2676.
doi: 10.3390/ijms19092676
94. Chen SF, Nieh S, Jao SW, Wu MZ, Liu CL, Chang YC, et al. The paracrine
effect of cancer-associated fibroblast-induced interleukin-33 regulates the
invasiveness of head and neck squamous cell carcinoma. J Pathol. (2013)
231:180–9. doi: 10.1002/path.4226
95. Ding L, Ren J, Zhang D, Li Y, Huang X, Hu Q, et al. A novel stromal
lncRNA signature reprograms fibroblasts to promote the growth of oral
squamous cell carcinoma via LncRNA-CAF/interleukin-33. Carcinogenesis.
(2018) 39:397–406. doi: 10.1093/carcin/bgy006
96. Islam MS, Horiguchi K, Iino S, Kaji N, Mikawa S, Hori M, et al. Epidermal
growth factor is a critical regulator of the cytokine IL-33 in intestinal
epithelial cells. Br J Pharmacol. (2016) 173:2532–42. doi: 10.1111/bph.13535
97. Li Y, Shi J, Qi S, Zhang J, Peng D, Chen Z, et al. IL-33 facilitates proliferation
of colorectal cancer dependent on COX2/PGE2. J Exp Clin Cancer Res.
(2018) 37:196. doi: 10.1186/s13046-018-0839-7
98. Yang Z, Gao X, Wang J, Xu L, Zheng Y, Xu Y. Interleukin-33 enhanced the
migration and invasiveness of human lung cancer cells. Onco Targets Ther.
(2018) 11:843–9. doi: 10.2147/OTT.S155905
99. Andersson P, Yang Y, Hosaka K, Zhang Y, Fischer C, BraunH, et al. Molecular
mechanisms of IL-33-mediated stromal interactions in cancer metastasis. JCI
Insight. (2018) 3:122375. doi: 10.1172/jci.insight.122375
100. Akimoto M, Maruyama R, Takamaru H, Ochiya T, Takenaga K. Soluble
IL-33 receptor sST2 inhibits colorectal cancer malignant growth by
modifying the tumour microenvironment. Nat Commun. (2016) 7:13589.
doi: 10.1038/ncomms13589
101. Akimoto M, Hayashi JI, Nakae S, Saito H, Takenaga K. Interleukin-33
enhances programmed oncosis of ST2L-positive low-metastatic cells in the
tumour microenvironment of lung cancer. Cell Death Dis. (2016) 7:e2057.
doi: 10.1038/cddis.2015.418
102. Wang L, Li H, Liang F, Hong Y, Jiang S, Xiao L. Examining IL-33 expression
in the cervix of HPV-infected patients: a preliminary study comparing IL-33
levels in different stages of disease and analyzing its potential association with
IFN-gamma.Med Oncol. (2014) 31:143. doi: 10.1007/s12032-014-0143-0
103. Musolino C, Allegra A, Profita M, Alonci A, Saitta S, Russo S, et al.
Reduced IL-33 plasma levels in multiple myeloma patients are associated
with more advanced stage of disease. Br J Haematol. (2013) 160:709–10.
doi: 10.1111/bjh.12146
104. Kim MS, Kim E, Heo JS, Bae DJ, Lee JU, Lee TH, et al. Circulating IL-33
level is associated with the progression of lung cancer. Lung Cancer. (2015)
90:346–51. doi: 10.1016/j.lungcan.2015.08.011
105. O’Donnell C, Mahmoud A, Keane J, Murphy C, White D, Carey S, et al.
An antitumorigenic role for the IL-33 receptor, ST2L, in colon cancer. Br
J Cancer. (2016) 114:37–43. doi: 10.1038/bjc.2015.433
106. Saranchova I, Han J, Huang H, Fenninger F, Choi KB, Munro L, et al.
Discovery of a metastatic immune escape mechanism initiated by the loss of
expression of the tumour biomarker interleukin-33. Sci Rep. (2016) 6:30555.
doi: 10.1038/srep30555
107. Gao X, Wang X, Yang Q, Zhao X, Wen W, Li G, et al. Tumoral
expression of IL-33 inhibits tumor growth and modifies the tumor
Frontiers in Immunology | www.frontiersin.org 14 June 2019 | Volume 10 | Article 1197
Baker et al. IL-1 Family Members in Cancer
microenvironment through CD8+ T and NK cells. J Immunol. (2015)
194:438–45. doi: 10.4049/jimmunol.1401344
108. Gao K, Li X, Zhang L, Bai L, Dong W, Gao K, et al. Transgenic
expression of IL-33 activates CD8(+) T cells and NK cells and inhibits
tumor growth and metastasis in mice. Cancer Lett. (2013) 335:463–71.
doi: 10.1016/j.canlet.2013.03.002
109. Qin L, Dominguez D, Chen S, Fan J, Long A, Zhang M, et al. Exogenous IL-
33 overcomes T cell tolerance in murine acute myeloid leukemia.Oncotarget.
(2016) 7:61069–80. doi: 10.18632/oncotarget.11179
110. Dominguez D, Ye C, Geng Z, Chen S, Fan J, Qin L, et al. Exogenous IL-
33 restores dendritic cell activation and maturation in established cancer. J
Immunol. (2017) 198:1365–75. doi: 10.4049/jimmunol.1501399
111. Lucarini V, Ziccheddu G, Macchia I, La Sorsa V, Peschiaroli F, Buccione
C, et al. IL-33 restricts tumor growth and inhibits pulmonary metastasis
in melanoma-bearing mice through eosinophils. Oncoimmunology. (2017)
6:e1317420. doi: 10.1080/2162402X.2017.1317420
112. Gabay C, Towne JE. Regulation and function of interleukin-36 cytokines in
homeostasis and pathological conditions. J Leukoc Biol. (2015) 97:645–52.
doi: 10.1189/jlb.3RI1014-495R
113. Bassoy EY, Towne JE, Gabay C. Regulation and function of interleukin-36
cytokines. Immunol Rev. (2018) 281:169–78. doi: 10.1111/imr.12610
114. Sullivan GP, Henry CM, Clancy DM, Mametnabiev T, Belotcerkovskaya E,
Davidovich P, et al. Suppressing IL-36-driven inflammation using peptide
pseudosubstrates for neutrophil proteases. Cell Death Dis. (2018) 9:378.
doi: 10.1038/s41419-018-0385-4
115. Wang X, Zhao X, Feng C, Weinstein A, Xia R, Wen W, et al. IL-36gamma
transforms the tumor microenvironment and promotes type 1 lymphocyte-
mediated antitumor immune responses. Cancer Cell. (2015) 28:296–306.
doi: 10.1016/j.ccell.2015.07.014
116. Chen Y, Sun J, Huang Y, Liu Y, Liang L, Yang D, et al. Targeted codelivery
of doxorubicin and IL-36gamma expression plasmid for an optimal chemo-
gene combination therapy against cancer lung metastasis. Nanomedicine.
(2019) 15:129–41. doi: 10.1016/j.nano.2018.09.005
117. Weinstein AM, Chen L, Brzana EA, Patil PR, Taylor JL, Fabian KL, et al.
Tbet and IL-36gamma cooperate in therapeutic DC-mediated promotion
of ectopic lymphoid organogenesis in the tumor microenvironment.
Oncoimmunology. (2017) 6:e1322238. doi: 10.1080/2162402X.2017.1322238
118. Sautes-Fridman C, Lawand M, Giraldo NA, Kaplon H, Germain C, Fridman
WH, et al. Tertiary lymphoid structures in cancers: prognostic value,
regulation, and manipulation for therapeutic intervention. Front Immunol.
(2016) 7:407. doi: 10.3389/fimmu.2016.00407
119. Weinstein AM, Giraldo NA, Petitprez F, Julie C, Lacroix L, Peschaud
F, et al. Association of IL-36gamma with tertiary lymphoid structures
and inflammatory immune infiltrates in human colorectal cancer. Cancer
Immunol Immunother. (2019) 68:109–20. doi: 10.1007/s00262-018-2259-0
120. Chang L, Guo R, Yuan Z. IL-36alpha suppresses proliferation of
ovarian cancer cells. Tumour Biol. (2017) 39:1010428317706918.
doi: 10.1177/1010428317706918
121. Wang ZS, Cong ZJ, Luo Y, Mu YF, Qin SL, Zhong M, et al. Decreased
expression of interleukin-36alpha predicts poor prognosis in colorectal
cancer patients. Int J Clin Exp Pathol. (2014) 7:8077–81.
122. Pan QZ, Pan K, Zhao JJ, Chen JG, Li JJ, Lv L, et al. Decreased
expression of interleukin-36alpha correlates with poor prognosis in
hepatocellular carcinoma. Cancer Immunol Immunother. (2013) 62:1675–85.
doi: 10.1007/s00262-013-1471-1
123. Boraschi D, Lucchesi D, Hainzl S, Leitner M, Maier E, Mangelberger D, et al.
IL-37: a new anti-inflammatory cytokine of the IL-1 family. Eur Cytokine
Netw. (2011) 22:127–147. doi: 10.1684/ecn.2011.0288
124. Cavalli G, Dinarello CA. Suppression of inflammation and
acquired immunity by IL-37. Immunol Rev. (2018) 281:179–90.
doi: 10.1111/imr.12605
125. Li S, Neff CP, Barber K, Hong J, Luo Y, Azam T, et al. Extracellular forms of
IL-37 inhibit innate inflammation in vitro and in vivo but require the IL-1
family decoy receptor IL-1R8. Proc Natl Acad Sci USA. (2015) 112:2497–502.
doi: 10.1073/pnas.1424626112
126. Li S, Amo-Aparicio J, Neff CP, Tengesdal IW, Azam T, Palmer BE, et al. Role
for nuclear interleukin-37 in the suppression of innate immunity. Proc Natl
Acad Sci USA. (2019) 21:201821111. doi: 10.1073/pnas.1821111116
127. Huo J, Hu J, Liu G, Cui Y, Ju Y. Elevated serum interleukin-37
level is a predictive biomarker of poor prognosis in epithelial ovarian
cancer patients. Arch Gynecol Obstet. (2017) 295:459–65. doi: 10.1007/
s00404-016-4258-8
128. Lin L, Wang J, Liu D, Liu S, Xu H, Ji N, et al. Interleukin-
37 expression and its potential role in oral leukoplakia and oral
squamous cell carcinoma. Sci Rep. (2016) 6:26757. doi: 10.1038/
srep26757
129. Yang T, Lin Q, Zhao M, Hu Y, Yu Y, Jin J, et al. IL-37 Is a Novel
proangiogenic factor of developmental and pathological angiogenesis.
Arterioscler Thromb Vasc Biol. (2015) 35:2638–46. doi: 10.1161/
ATVBAHA.115.306543
130. Luo C, Shu Y, Luo J, Liu D, Huang DS, Han Y, et al. Intracellular IL-
37b interacts with Smad3 to suppress multiple signaling pathways and
the metastatic phenotype of tumor cells. Oncogene. (2017) 36:2889–99.
doi: 10.1038/onc.2016.444
131. Jiang Y, Wang Y, Liang L, Gao Y, Chen J, Sun Y, et al. IL-37 mediates
the antitumor activity in renal cell carcinoma. Med Oncol. (2015) 32:250.
doi: 10.1007/s12032-015-0695-7
132. Zhao JJ, Pan QZ, Pan K, Weng DS, Wang QJ, Li JJ, et al. Interleukin-
37 mediates the antitumor activity in hepatocellular carcinoma:
role for CD57+ NK cells. Sci Rep. (2014) 4:5177. doi: 10.1038/
srep05177
133. Li Y, Zhao M, Guo C, Chu H, Li W, Chen X, et al. Intracellular mature IL-37
suppresses tumor metastasis via inhibiting Rac1 activation.Oncogene. (2018)
37:1095–106. doi: 10.1038/onc.2017.405
134. Gao W, Kumar S, Lotze MT, Hanning C, Robbins PD, Gambotto
A. Innate immunity mediated by the cytokine IL-1 homologue 4
(IL-1H4/IL-1F7) induces IL-12-dependent adaptive and profound
antitumor immunity. J Immunol. (2003) 170:107–13. doi: 10.4049/
jimmunol.170.1.107
135. Liu R, Tang C, Shen A, Luo H, Wei X, Zheng D, et al. IL-
37 suppresses hepatocellular carcinoma growth by converting
pSmad3 signaling from JNK/pSmad3L/c-Myc oncogenic signaling to
pSmad3C/P21 tumor-suppressive signaling. Oncotarget. (2016) 7:85079–96.
doi: 10.18632/oncotarget.13196
136. Wang S, An W, Yao Y, Chen R, Zheng X, Yang W, et al. Interleukin
37 Expression Inhibits STAT3 to Suppress the Proliferation and
Invasion of Human Cervical Cancer Cells. J Cancer. (2015) 6:962–9.
doi: 10.7150/jca.12266
137. Jiang M, Wang Y, Zhang H, Ji Y, Zhao P, Sun R, et al. IL-37 inhibits
invasion and metastasis in non-small cell lung cancer by suppressing
the IL-6/STAT3 signaling pathway. Thorac Cancer. (2018) 9:621–9.
doi: 10.1111/1759-7714.12628
138. Yan X, Zhao J, Zhang R. Interleukin-37 mediates the antitumor activity in
colon cancer through beta-catenin suppression. Oncotarget. (2017) 8:49064–
75. doi: 10.18632/oncotarget.17093
139. Chen YH, Zhou BY, Wu XJ, Xu JF, Zhang JA, Chen YH, et al. CCL22 and IL-
37 inhibit the proliferation and epithelial-mesenchymal transition process of
NSCLC A549 cells. Oncol Rep. (2016) 36:2017–24. doi: 10.3892/or.2016.4995
140. Wu TJ, Xu B, Zhao GH, Luo J, Luo C. IL-37 suppresses migration
and invasion of gallbladder cancer cells through inhibition
of HIF-1alpha induced epithelial-mesenchymal transition. Eur
Rev Med Pharmacol Sci. (2018) 22:8179–85. doi: 10.26355/
eurrev_201812_16510
141. Senovilla L, Vacchelli E, Galon J, Adjemian S, Eggermont A, Fridman WH,
et al. Trial watch: prognostic and predictive value of the immune infiltrate in
cancer. Oncoimmunology. (2012) 1:1323–43. doi: 10.4161/onci.22009
142. Nold MF, Nold-Petry CA, Zepp JA, Palmer BE, Bufler P, Dinarello CA. IL-
37 is a fundamental inhibitor of innate immunity. Nat Immunol. (2010)
11:1014–22. doi: 10.1038/ni.1944
143. Lin H, Ho AS, Haley-Vicente D, Zhang J, Bernal-Fussell J, Pace AM, et al.
Cloning and characterization of IL-1HY2, a novel interleukin-1 family
member. J Biol Chem. (2001) 276:20597–602. doi: 10.1074/jbc.M010095200
144. Bensen JT, Dawson PA, Mychaleckyj JC, Bowden DW. Identification
of a novel human cytokine gene in the interleukin gene cluster on
chromosome 2q12–14. J Interferon Cytokine Res. (2001) 21:899–904.
doi: 10.1089/107999001753289505
Frontiers in Immunology | www.frontiersin.org 15 June 2019 | Volume 10 | Article 1197
Baker et al. IL-1 Family Members in Cancer
145. van de Veerdonk FL, Stoeckman AK, Wu G, Boeckermann AN,
Azam T, Netea MG, et al. IL-38 binds to the IL-36 receptor and
has biological effects on immune cells similar to IL-36 receptor
antagonist. Proc Natl Acad Sci USA. (2012) 109:3001–5. doi: 10.1073/
pnas.1121534109
146. van de Veerdonk FL, de Graaf DM, Joosten LA, Dinarello CA. Biology
of IL-38 and its role in disease. Immunol Rev. (2018) 281:191–6.
doi: 10.1111/imr.12612
147. Garraud T, Harel M, Boutet MA, Le Goff B, Blanchard F. The enigmatic
role of IL-38 in inflammatory diseases. Cytokine Growth Factor Rev. (2018)
39:26–35. doi: 10.1016/j.cytogfr.2018.01.001
148. Boutet MA, Najm A, Bart G, Brion R, Touchais S, Trichet V, et al. IL-38
overexpression induces anti-inflammatory effects in mice arthritis models
and in human macrophages in vitro. Ann Rheum Dis. (2017) 76:1304–12.
doi: 10.1136/annrheumdis-2016-210630
149. Takada K, Okamoto T, Tominaga M, Teraishi K, Akamine T, Takamori S,
et al. Clinical implications of the novel cytokine IL-38 expressed in lung
adenocarcinoma: Possible association with PD-L1 expression. PLoS ONE.
(2017) 12:e0181598. doi: 10.1371/journal.pone.0181598
150. Wang F, Zhang W, Wu T, Chu H. Reduced interleukin-38 in non-small
cell lung cancer is associated with tumour progression. Open Biol. (2018)
8:180132. doi: 10.1098/rsob.180132
151. Mora J, Schlemmer A, Wittig I, Richter F, Putyrski M, Frank
AC, et al. Interleukin-38 is released from apoptotic cells to limit
inflammatory macrophage responses. J Mol Cell Biol. (2016) 17:mjw006.
doi: 10.1093/jmcb/mjw006
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2019 Baker, Houston and Brint. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Immunology | www.frontiersin.org 16 June 2019 | Volume 10 | Article 1197
